Search Results 21-30 of 16621 for %E2%80%A2%09Pituitary%20Insufficiency
This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, phase 2 study in subjects with Type 2 ...
The goal of this study is to determine the role of postprandial glucagon suppression and insulin secretion in the progression of glucose intolerance in people ...
I went to my primary care physician and was told it was nothing to worry about. Within one month, five more lumps formed on my right arm. My physician scheduled ...
Response will be assessed per RECIST 1.1; patients will have CT/MRI ~Q8WK (2 cycles) on study. Patients will have tumor biopsies at screening and EOT to ...
... 2) a reduced rate of complications associated with feeding tubes, such as leakage, skin breakdown, etc.; 3) ease of use; and 4) durability (holds up to ...
Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules. Participation eligibility. Participant eligibility includes age, gender ...
About this study. This will be a single-center, randomized, parallel group, multiple dose administration, double-blind, placebo-controlled study to evaluate ...
Participation eligibility · Weight loss ≥ 10% within the previous 6 months · Extreme fatigue attributed to CLL · Fevers > 100.5° Fahrenheit (F) for 2 weeks ...
Blood sugar levels start to rise even before you get type 2 diabetes. Find out what steps you can take to prevent diabetes from developing.
The research interests of Urshila Durani, M.D., M.P.H., a Mayo Clinic hematologist, focus on improving cancer care delivery.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.